Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_1
5
100%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

terminated240%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

NCT03589651
completedphase_1

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

NCT02646748
completedphase_1

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

NCT03688152
terminatedphase_1

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

NCT02265510
terminatedphase_1

Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

NCT02559492

Clinical Trials (5)

Showing 5 of 5 trials
NCT03589651Phase 1

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Completed
NCT02646748Phase 1

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Completed
NCT03688152Phase 1

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

Completed
NCT02265510Phase 1

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Terminated
NCT02559492Phase 1

Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5